RecruitingNCT06984445
Cord Blood S100B Protein Levels in Neonates Following Intrauterine Transfusions for HDFN-Associated Fetal Anemia
Studying Hemolytic disease due to fetomaternal alloimmunization
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Institute of Mother and Child, Warsaw, Poland
- Principal Investigator
- Agnieszka A. Drozdowska-Szymczak, MD, PhDInstitute of Mother and Child in Warsaw, Poland
- Intervention
- Cord blood S100B protein level prior to IUT(diagnostic_test)
- Enrollment
- 180 enrolled
- Eligibility
- 18 years · FEMALE
- Timeline
- 2024 – 2026
Study locations (1)
- Institute of Mother and Child, Warsaw, Poland
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06984445 on ClinicalTrials.govOther trials for Hemolytic disease due to fetomaternal alloimmunization
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07194070A Study on Hemolytic Disease of the Fetus and Newborn (HDFN) Through Global RegistryJanssen Research & Development, LLC
- RECRUITINGPHASE3NCT05912517A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)Janssen Research & Development, LLC
See all trials for Hemolytic disease due to fetomaternal alloimmunization →